Posted by Michael Wonder on 17 Sep 2022
Heron Therapeutics announces US FDA approval of Aponvie (HTX-019) for the prevention of post-operative nausea and vomiting
16 September 2022 - Aponvie is the first and only intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for post-operative nausea and vomiting.
Heron Therapeutics today announced that the US FDA has approved Aponvie (aprepitant) injectable emulsion, for intravenous use for the prevention of post-operative nausea and vomiting in adults.
